A$15 billion Molecular Imaging Market IBX - sole ASX player, page-5

I hope everyone reads this and saves it because I will be bringing this post back up towards the end of year to check on progress.

"Harvey said.“MagSense brings precision and specificity to breast cancer imaging,” she said.“The technology has the promise of fewer false alarms and fewer overlooked cancers.“Like a pregnancy test that is pink or blue, the MagSense technology could provide an accurate yes or no answer to MRI as to whether cancer is present, and thereby enable a more personalised treatment the woman will receive.“This innovative tool will transform cancer detection and care, starting with HER2+ breast cancer.”

First of all, Harvey is no where near being up to speed in the world of new imaging and theranostic isotope drug development. Feel free to ask her.

She too has scored a cushy job like Bob within IBX. She is on the payroll so of course she will beat the IBX drum as the above paragraph states.

She says this tech has "promise". Of course she would say that. She's getting paid to say that even though the ph 1 trial (if you could call it a trial) FAILED.
Think about it. There won't be the progression of a phase II trial if phase I has failed.
She says "The MagSense imaging agent 'could' potentially reduce the need for lymph node biopsies"
She can't say that it will because the results failed to prove this.
'Could' in science terms is nowhere near being called a breakthrough technology.

Meanwhile, other new isotope tech, decades ahead IBX tech, has already proved that biopsies will not be needed with outstanding results in picking up cancer cells less than half the size of current 'best in class' practice procedures and has proven that best current practice are failing to locate and image all cancer cells in the body 80% of the time. These new patented double ligand isotopes are showing that not only will they specifically bind to the cancer cell but also extremely effective in destroying it.

Good luck.

Believe what you are only capable of believing.